Overview

Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Status:
Recruiting

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

PACE is a prospective multicenter single-arm investigator-initiated phase II trial that examines the value of a treatment escalation strategy by the addition of platinum-based doublet chemotherapy to osimertinib in patients with treatment-naïve NSCLC harboring L858R or del19 EGFR mutation who are suspected to have poor response upon single-agent TKI treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Goethe University

Treatments:

Carboplatin
Osimertinib
Pemetrexed